Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 11.42 2.98% 0.33
ALNA closed up 2.98 percent on Thursday, September 20, 2018, on approximately normal volume. It was able to find support at its 50 day moving average. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical ALNA trend table...

Date Alert Name Type % Chg
Sep 20 50 DMA Support Bullish 0.00%
Sep 20 Crossed Above 200 DMA Bullish 0.00%
Sep 20 BB Squeeze Ended Range Expansion 0.00%
Sep 20 Above Upper BB Strength 0.00%
Sep 20 Up 3 Days in a Row Strength 0.00%
Sep 20 Upper Bollinger Band Touch Strength 0.00%
Sep 19 Crossed Above 20 DMA Bullish 2.98%
Sep 19 Crossed Above 50 DMA Bullish 2.98%
Sep 19 MACD Bullish Signal Line Cross Bullish 2.98%
Sep 19 Bollinger Band Squeeze Range Contraction 2.98%

Older signals for ALNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Is ALNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.56
52 Week Low 6.13
Average Volume 68,068
200-Day Moving Average 11.3987
50-Day Moving Average 10.809
20-Day Moving Average 10.778
10-Day Moving Average 10.742
Average True Range 0.8006
ADX 17.78
+DI 25.8809
-DI 11.6088
Chandelier Exit (Long, 3 ATRs ) 9.5982
Chandelier Exit (Short, 3 ATRs ) 12.6118
Upper Bollinger Band 11.3872
Lower Bollinger Band 10.1688
Percent B (%b) 1.03
BandWidth 11.304509
MACD Line -0.0175
MACD Signal Line -0.0957
MACD Histogram 0.0781
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.83
Resistance 3 (R3) 12.78 12.26 12.60
Resistance 2 (R2) 12.26 11.90 12.29 12.52
Resistance 1 (R1) 11.84 11.68 12.05 11.89 12.44
Pivot Point 11.32 11.32 11.43 11.35 11.32
Support 1 (S1) 10.90 10.96 11.11 10.95 10.40
Support 2 (S2) 10.38 10.74 10.41 10.32
Support 3 (S3) 9.96 10.38 10.25
Support 4 (S4) 10.01